RxDoctor Payments Data

Anna Walker, PA

Physician Assistant · Augusta, GANPI 1386154045

Payments from drug & device makers

$4,418in general payments, 2019–2025

Across 103 payments — averaging $42.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$682
  • Janssen Scientific Affairs, LLC$457
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$193
  • Lilly USA, LLC$175
  • QOL Medical, LLC$154
  • plus $683 from 15 others

What the payments were for

  • Food & beverage$4,31998%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,418 in reported general payments places this provider in the 85th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$12,691
Medicare patients
111
Services billed
171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab40$1,013,319
Humira(Cf) PenAdalimumab14$196,433
RemicadeInfliximab19$187,906
LinzessLinaclotide172$115,436
RinvoqUpadacitinib11$92,077
CreonLipase/Protease/Amylase28$77,988
ZenpepLipase/Protease/Amylase11$44,316
XifaxanRifaximin16$34,635
MotegrityPrucalopride Succinate26$23,819
MovantikNaloxegol Oxalate21$10,826
Mesalamine29$4,354
Colestipol Hcl22$1,852
Omeprazole129$1,427
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl34$533
Pantoprazole Sodium47$322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Remicade$682$1,201,22559 claims
AbbVieLinzess, Rinvoq, Creon$2,075$285,501211 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$193$34,63516 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$50$23,81926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →